SB-334,867

SB-334,867
IUPAC ime
1-(2-methylbenzoxazol- 6-yl)- 3-[1,5]naphthyridin- 4-yl urea
Identifikatori
CAS broj249889-64-3
PubChemCID 6604926
IUPHAR/BPS1703
ChemSpider5037182 ДаY
ChEMBLCHEMBL291536 ДаY
Hemijski podaci
FormulaC17H13N5O2
Molarna masa319.317 g/mol
SMILES
  • O=C(Nc1c2ncccc2ncc1)Nc3ccc4nc(oc4c3)C
InChI
  • InChI=1S/C17H13N5O2/c1-10-20-12-5-4-11(9-15(12)24-10)21-17(23)22-14-6-8-18-13-3-2-7-19-16(13)14/h2-9H,1H3,(H2,18,21,22,23) ДаY
  • Key:AKMNUCBQGHFICM-UHFFFAOYSA-N ДаY

SB-334,867 je lek koji je bio prvi ne-peptidni selektivni antagonist oreksinskog receptora, tip OX1. On je oko 50 puta selektivniji za OX1 nego OX2 receptor.[1] Bilo je pokazano da proizvodi sedativne i anoreksične efekte kod životinja,[2] i bio je koristan za karakterizaciju oreksinske regulacije moždanih sistema za apetit i san,[3][4][5][6][7][8] kao i drugih fizioloških procesesa.[9][10][11][12] Oreksinski antagonisti imaju više mogućih kliničkih primena, kao što je tretman zavisnosti od droga, insomnije, gojaznosti i dijabetesa.[13][14][15][16][17][18][19]

Literatura

  1. ^ Smart, D; Sabido-David, C; Brough, SJ; Jewitt, F; Johns, A; Porter, RA; Jerman, JC (2001). „SB-334867-A: the first selective orexin-1 receptor antagonist”. British journal of pharmacology. 132 (6): 1179—82. PMC 1572677 Слободан приступ. PMID 11250867. doi:10.1038/sj.bjp.0703953. 
  2. ^ Rodgers, RJ; Halford, JC; Nunes De Souza, RL; Canto De Souza, AL; Piper, DC; Arch, JR; Upton, N; Porter, RA; Johns, A (2001). „SB-334867, a selective orexin-1 receptor antagonist, enhances behavioural satiety and blocks the hyperphagic effect of orexin-A in rats”. The European journal of neuroscience. 13 (7): 1444—52. PMID 11298806. doi:10.1046/j.0953-816x.2001.01518.x. 
  3. ^ Haynes, AC; Chapman, H; Taylor, C; Moore, GB; Cawthorne, MA; Tadayyon, M; Clapham, JC; Arch, JR (2002). „Anorectic, thermogenic and anti-obesity activity of a selective orexin-1 receptor antagonist in ob/ob mice”. Regulatory peptides. 104 (1-3): 153—9. PMID 11830290. doi:10.1016/S0167-0115(01)00358-5. 
  4. ^ Rodgers, RJ; Ishii, Y; Halford, JC; Blundell, JE (2002). „Orexins and appetite regulation”. Neuropeptides. 36 (5): 303—25. PMID 12450737. 
  5. ^ Bernard, R; Lydic, R; Baghdoyan, HA (2003). „Hypocretin-1 causes G protein activation and increases ACh release in rat pons”. The European journal of neuroscience. 18 (7): 1775—85. PMID 14622212. doi:10.1046/j.1460-9568.2003.02905.x. 
  6. ^ Soffin, EM; Gill, CH; Brough, SJ; Jerman, JC; Davies, CH (2004). „Pharmacological characterisation of the orexin receptor subtype mediating postsynaptic excitation in the rat dorsal raphe nucleus”. Neuropharmacology. 46 (8): 1168—76. PMID 15111023. doi:10.1016/j.neuropharm.2004.02.014. 
  7. ^ Thorpe, AJ; Kotz, CM (2005). „Orexin a in the nucleus accumbens stimulates feeding and locomotor activity”. Brain research. 1050 (1-2): 156—62. PMID 15979595. doi:10.1016/j.brainres.2005.05.045. 
  8. ^ Frederick-Duus, D; Guyton, MF; Fadel, J (2007). „Food-elicited increases in cortical acetylcholine release require orexin transmission”. Neuroscience. 149 (3): 499—507. PMID 17928158. doi:10.1016/j.neuroscience.2007.07.061. 
  9. ^ Small, CJ; Goubillon, ML; Murray, JF; Siddiqui, A; Grimshaw, SE; Young, H; Sivanesan, V; Kalamatianos, T; Kennedy, AR (2003). „Central orexin a has site-specific effects on luteinizing hormone release in female rats”. Endocrinology. 144 (7): 3225—36. PMID 12810579. doi:10.1210/en.2002-0041. 
  10. ^ D'anna, KL; Gammie, SC (2006). „Hypocretin-1 dose-dependently modulates maternal behaviour in mice”. Journal of neuroendocrinology. 18 (8): 553—66. PMC 2275401 Слободан приступ. PMID 16867176. doi:10.1111/j.1365-2826.2006.01448.x. 
  11. ^ Muschamp, JW; Dominguez, JM; Sato, SM; Shen, RY; Hull, EM (2007). „A role for hypocretin (orexin) in male sexual behavior”. The Journal of neuroscience : the official journal of the Society for Neuroscience. 27 (11): 2837—45. PMID 17360905. doi:10.1523/JNEUROSCI.4121-06.2007. 
  12. ^ Eliassi, A; Nazari, M; Naghdi, N (2009). „Role of the ventromedial hypothalamic orexin-1 receptors in regulation of gastric Acid secretion in conscious rats”. Journal of neuroendocrinology. 21 (3): 177—82. PMID 19207823. doi:10.1111/j.1365-2826.2009.01824.x. 
  13. ^ Smart, D; Haynes, AC; Williams, G; Arch, JR (2002). „Orexins and the treatment of obesity”. European journal of pharmacology. 440 (2-3): 199—212. PMID 12007536. doi:10.1016/S0014-2999(02)01429-2. 
  14. ^ Bingham, MJ; Cai, J; Deehan, MR (2006). „Eating, sleeping and rewarding: orexin receptors and their antagonists”. Current opinion in drug discovery & development. 9 (5): 551—9. PMID 17002215. 
  15. ^ Borgland, SL; Taha, SA; Sarti, F; Fields, HL; Bonci, A (2006). „Orexin a in the VTA is critical for the induction of synaptic plasticity and behavioral sensitization to cocaine”. Neuron. 49 (4): 589—601. PMID 16476667. doi:10.1016/j.neuron.2006.01.016. 
  16. ^ Narita, M; Nagumo, Y; Hashimoto, S; Narita, M; Khotib, J; Miyatake, M; Sakurai, T; Yanagisawa, M; Nakamachi, T (2006). „Direct involvement of orexinergic systems in the activation of the mesolimbic dopamine pathway and related behaviors induced by morphine”. The Journal of neuroscience : the official journal of the Society for Neuroscience. 26 (2): 398—405. PMID 16407535. doi:10.1523/JNEUROSCI.2761-05.2006. 
  17. ^ Lawrence, AJ; Cowen, MS; Yang, HJ; Chen, F; Oldfield, B (2006). „The orexin system regulates alcohol-seeking in rats”. British journal of pharmacology. 148 (6): 752—9. PMC 1617074 Слободан приступ. PMID 16751790. doi:10.1038/sj.bjp.0706789. 
  18. ^ Sharf, R; Sarhan, M; Dileone, RJ (2008). „Orexin mediates the expression of precipitated morphine withdrawal and concurrent activation of the nucleus accumbens shell”. Biological psychiatry. 64 (3): 175—83. PMC 2529153 Слободан приступ. PMID 18423425. doi:10.1016/j.biopsych.2008.03.006. 
  19. ^ Aston-Jones, G; Smith, RJ; Moorman, DE; Richardson, KA (2009). „Role of lateral hypothalamic orexin neurons in reward processing and addiction”. Neuropharmacology. 56 Suppl 1: 112—21. PMC 2635332 Слободан приступ. PMID 18655797. doi:10.1016/j.neuropharm.2008.06.060. 

Spoljašnje veze

  • p
  • r
  • u
GABAA receptor
Barbiturati
  • Ultra kratkotrajni
    Kratko/srednje
    trajni
    Dugotrajni
    Negrupisani
    Benzodiazepini
    Kratkotrajni
    Intermedijerno trajni
    Dugotrajni
    Dialkil-fenoli
    Nebenzodijazepini
    Piperidindioni
    Hinazolinoni
    Neuroaktivni steroidi
    Alfa-2-adrenergički
    receptor
    Alfa-adrenergički agonisti
    Melatoninski receptor
    Melatonin
    Histaminski receptor &
    Acetilholinski receptor
    Antihistamini &
    Antiholinergici
    5-HT2A &
    α1- adrenergički
    Selektivni 5-HT2A & α1-adrenergički antagonisti
    GABAB receptor /
    GHB receptor
    GHB Tip
    Oreksinski receptori
    Oreksinski antagonisti
    Drugi receptori/
    negrupisani
    Aldehidi
    Alkini
    Karbamati
    Drugi
    • p
    • r
    • u
    Holecistokinin
    CCKA
    Agonisti: Holecistokinin • CCK-4
    Antagonisti: Asperlicin • Proglumid • Lorglumid • Devazepid • Deksloksiglumid
    CCKB
    Agonisti: Holecistokinin • CCK-4 • Gastrin
    Antagonisti: Proglumid • CI-988
    CRH
    CRF1
    CRF2
    Galanin
    GAL1
    Agonisti: Galanin • Galaninu-sličan peptid • Galmic • Galnon
    GAL2
    Agonisti: Galanin • Galaninu-sličan peptid • Galmic • Galnon
    GAL3
    Agonisti: Galanin • Galmic • Galnon
    Grelin
    Agonisti: Grelin • Kapromorelin • MK-677 • Sermorelin • SM-130,686 • Tabimorelin
    MCH
    MCH1
    MCH2
    Melanokortin
    MC1
    MC2
    Agonisti: ACTH • Kosintropin • Tetrakosaktid
    MC3
    Agonisti: alfa-MSH • Bremelanotid • Melanotan II
    MC4
    Agonisti: alfa-MSH • Bremelanotid • Melanotan II • THIQ
    Antagonisti: Agutiju srodni peptid
    MC5
    Agonisti: alfa-MSH • Melanotan II
    Neuropeptid S
    Agonisti: Neuropeptid S
    Antagonisti: SHA-68
    Neuropeptid Y
    Y1
    Agonisti: Neuropeptid Y • Peptid YY
    Antagonisti: BIBP-3226
    Y2
    Agonisti: Neuropeptid Y • Peptid YY
    Antagonisti: BIIE-0246
    Y4
    Agonisti: Neuropeptid Y • Pankreasni polipeptid • Peptid YY
    Antagonisti: UR-AK49
    Y5
    Agonisti: Neuropeptid Y • Peptid YY
    Antagonisti: Lu AA-33810
    Neurotenzin
    NTS1
    Agonisti: Neurotenzin • Neuromedin N
    Antagonisti: SR-48692 • SR-142,948
    NTS2
    Agonisti: Neurotenzin
    Antagonisti: Levokabastin • SR-142,948
    Opioid
    vidi Opioidi
    Oreksin
    OX1
    Agonisti: Oreksin-A
    Antagonisti: Almoreksant • SB-334,867 • SB-408,124 • SB-649,868
    OX2
    Agonisti: Oreksin-A
    Antagonisti: Almoreksant • SB-649,868 • TCS-OX2-29
    Oksitocin
    Agonisti: Karbetocin • Demoksitocin • Oksitocin • WAY-267,464
    Antagonisti: Atosiban • L-371,257 • L-368,899
    Tahikinin
    NK1
    Agonisti: Supstanca P
    Antagonisti: Aprepitant • Befetupitant • Kasopitant • CI-1021 • CP-96,345 • CP-99,994 • CP-122,721 • Dapitant • Ezlopitant • FK-888 • Fosaprepitant • GR-203,040 • GW-597,599 • HSP-117 • L-733,060 • L-741,671 • L-743,310 • L-758,298 • Lanepitant • LY-306,740 • Maropitant • Netupitant • NKP-608 • Nolpitantium • Orvepitant • RP-67,580 • SDZ NKT 343 • Vestipitant • Vofopitant
    NK2
    Agonisti: Neurokinin A
    Antagonisti: GR-159897 • Ibodutant • Saredutant
    NK3
    Agonisti: Neurokinin B
    Antagonisti: Osanetant • Talnetant
    Vazopresin
    V1A
    Agonisti: Dezmopresin • Felipresin • Ornipresin • Terlipresin • Vazopresin
    Antagonisti: Konivaptan • Demeklociklin • Relkovaptan
    V1B
    Agonisti: Felipresin • Ornipresin • Terlipresin • Vazopresin
    Antagonisti: Demeklociklin • Nelivaptan
    V2
    Agonisti: Dezmopresin • Ornipresin • Vazopresin
    Antagonisti: Konivaptan • Demeklociklin • Liksivaptan • Mozavaptan • Satavaptan • Tolvaptan


    Molimo Vas, obratite pažnju na važno upozorenje
    u vezi sa temama iz oblasti medicine (zdravlja).
    SB-334,867 na srodnim projektima Vikipedije:
    Podaci na Vikipodacima